2 news items
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
ATXI
FBIO
16 May 24
lead to cell death. A first-in-human Phase 1 study of AJ201 in 72 healthy volunteers revealed an excellent safety and pharmacokinetic profile
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
ATXI
FBIO
25 Mar 24
stress that can lead to cell death. AJ201 is currently being studied in a Phase 1b/2a multicenter, randomized, double-blind clinical trial in six
- Prev
- 1
- Next